Empagliflozin (Jardiance®). HTA ID: 21030

Assessment Status NCPE Assessment Process Complete
HTA ID 21030
Drug Empagliflozin
Brand Jardiance®
Indication For the treatment of symptomatic chronic heart failure with reduced ejection fraction.
Assessment Process
Rapid review commissioned 05/07/2021
Rapid review completed 29/07/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of empagliflozin compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 24/08/2021
Pre-submission consultation with Applicant 18/10/2021
Full submission received from Applicant 12/01/2022
Preliminary review sent to Applicant 28/02/2022
NCPE assessment re-commenced 28/03/2022
Factual accuracy sent to Applicant 30/03/2022
NCPE assessment re-commenced 07/04/2022
NCPE assessment completed 28/04/2022
NCPE assessment outcome The NCPE considers empagliflozin to be a cost-effective treatment for adults with symptomatic chronic heart failure with reduced ejection fraction and reimbursement is recommended*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Technical Summary

Plain English Summary

The HSE has approved reimbursement, December 2022.